Antibody
A single antibody molecule weighs approximately 150 kilodaltons and spans about 10 nanometers in size. This protein forms a distinctive Y shape composed of four polypeptide chains. Two identical heavy chains run along the outer arms of the letter, while two identical light chains occupy the inner space. Disulfide bonds connect these chains together to maintain structural integrity. Each chain consists of repeating domains that are roughly 110 amino acids long. These domains appear as rectangles in simplified diagrams but form complex three-dimensional structures in reality. The variable regions sit at the tips of the Y arms where antigen binding occurs. Three hypervariable loops within each variable domain create a unique surface for interaction. These loops fold into beta-strands that complement the shape of an incoming antigen like a lock fits a key. The constant region forms the trunk of the Y and determines how immune cells respond to bound targets.
Antibodies neutralize pathogens by blocking essential parts of their surfaces from invading host cells. They can also tag microbes for destruction by other components of the immune system. When an antibody binds to a bacterium it triggers the complement cascade through its Fc region. This process recruits phagocytes to engulf and digest the marked pathogen. Some antibodies activate natural killer cells to release cytotoxic molecules directly against infected targets. The Fc region serves as a docking site for effector molecules on macrophages or neutrophils. IgG antibodies cross the placenta to provide passive immunity to developing fetuses. IgA antibodies protect mucosal surfaces like the gut and respiratory tract from colonization. IgE antibodies trigger histamine release during allergic reactions or attacks against parasitic worms. Natural IgM antibodies exist before infection and help clear viruses in early immune phases. These diverse functions allow the body to adapt responses based on specific threats encountered.
Humans generate approximately 10 billion different antibodies despite having a limited number of genes. V(D)J recombination combines variable, diversity, and joining gene segments randomly in bone marrow. Each B cell selects one set of these segments to create a unique immunoglobulin gene. RAG proteins cut DNA at specific regions to enable this rearrangement process. Somatic hypermutation introduces point mutations after antigen activation to refine binding affinity. High-affinity variants survive while low-affinity versions undergo apoptosis. Class switching allows activated B cells to produce different antibody isotypes without changing specificity. This mechanism relies on switch regions found upstream of constant region genes. Non-homologous end joining rejoins broken DNA strands to form new isotype combinations. Memory B cells persist for decades to ensure rapid secondary responses upon re-exposure. Long-lived plasma cells reside in bone marrow niches to maintain steady antibody levels throughout life.
Paul Ehrlich first used the term Antikörper in an October 1891 article titled Experimental Studies on Immunity. Emil von Behring and Kitasato Shibasaburō described antibody activity against diphtheria toxins in 1890. Linus Pauling confirmed the lock-and-key theory in the 1940s by demonstrating shape-dependent interactions. Astrid Fagraeus discovered that plasma cells generate antibodies in 1948. Gerald Edelman and Joseph Gally identified the light chain structure in the early 1960s. Rodney Porter characterized Fab and Fc regions around the same time period. These scientists shared the 1972 Nobel Prize in Physiology or Medicine for their structural elucidation work. Susumu Tonegawa demonstrated genetic rearrangement mechanisms starting with experiments in 1976. Thomas Tomasi discovered secretory IgA while David S. Rowe and John L. Fahey found IgD. Kimishige Ishizaka and Teruko Ishizaka identified IgE as an allergy-related class during landmark research. The field evolved from theoretical speculation to precise molecular understanding over nearly a century of study.
Medical diagnostics rely heavily on detecting specific antibodies present in blood samples. Serology tests measure titers against Epstein-Barr virus or Lyme disease pathogens. Nephelometry quantifies individual immunoglobulin classes to characterize patient profiles. The Coombs test detects antibodies directed against red blood cell surface antigens in immune-mediated hemolytic anemia. Over-the-counter home pregnancy tests utilize human chorionic gonadotropin-directed antibodies for detection. Targeted monoclonal antibody therapies treat rheumatoid arthritis, multiple sclerosis, psoriasis, and various cancers including non-Hodgkin's lymphoma. Rho(D) immune globulin prevents sensitization in Rh-negative mothers carrying Rh-positive fetuses. Polyclonal antiserum comes from animals like horses or humans injected with specific antigens. Hybridoma technology fuses antibody-secreting cells with cancer lines to produce identical clones. Immunofluorescence images mark microtubules using green fluorescing molecules attached to antibodies. PET imaging employs radioactive fluoride labeling to visualize cancer progression through antibody targeting. These applications demonstrate how fundamental biological knowledge translates into life-saving medical interventions today.
Common questions
What is the weight and size of a single antibody molecule?
A single antibody molecule weighs approximately 150 kilodaltons and spans about 10 nanometers in size. This protein forms a distinctive Y shape composed of four polypeptide chains.
How do antibodies neutralize pathogens and trigger immune responses?
Antibodies neutralize pathogens by blocking essential parts of their surfaces from invading host cells. They can also tag microbes for destruction by other components of the immune system through processes like the complement cascade or activation of natural killer cells.
When did Paul Ehrlich first use the term Antikörper to describe antibodies?
Paul Ehrlich first used the term Antikörper in an October 1891 article titled Experimental Studies on Immunity. Emil von Behring and Kitasato Shibasaburō described antibody activity against diphtheria toxins in 1890 prior to this publication.
Which scientists shared the 1972 Nobel Prize in Physiology or Medicine for elucidating antibody structure?
Gerald Edelman, Joseph Gally, and Rodney Porter characterized the light chain structure and Fab and Fc regions around the early 1960s. These scientists shared the 1972 Nobel Prize in Physiology or Medicine for their structural elucidation work.
What medical applications utilize specific antibodies for diagnostics and treatment today?
Medical diagnostics rely heavily on detecting specific antibodies present in blood samples using serology tests or Nephelometry. Targeted monoclonal antibody therapies treat rheumatoid arthritis, multiple sclerosis, psoriasis, and various cancers including non-Hodgkin's lymphoma.